Memorial Sloan Kettering Cancer Center
Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (given one after another)-combined with local therapies (which treat cancer in a specific part of the body) and treatments that prevent cancer from spreading to the central nervous system (CNS; including the brain and spinal cord) can result in long-lasting remission and possibly cure some participants with HER2+ metastatic breast cancer.
Inclusion Criteria: * Male or female participants who are ≥18 years old with histologically confirmed diagnosis of unresectable locally advanced or MBC. * Stage IV at the diagnosis (i.e., de novo metastatic) as per AJCC 8. * HER2 IHC results of 3+. * Life expectancy of ≥12 weeks. * Must be deemed medically fit for surgery and be surgical candidates upfront, or potentially operable if there is response to induction therapy. * Must have measurable disease per PERCIST 1.0. * The participant (or legally acceptable representative if applicable) provides written informed consent for the trial. * Ha…
The use of this assay is expected to optimize treatment without introducing significant new risks or deviating from approved therapeutic protocols.
The use of this assay is expected to optimize treatment without introducing significant new risks or deviating from approved therapeutic protocols.
T-DXd is a HER2-targeting antibody drug conjugate that consists of an anti-HER2 antibody.
intravenous (IV) infusion